Definitions

1. Few SAEs were reported (1.4% for rosuvastatin 10 mg, 1.2% for atorvastatin 20 mg) and no drug-related SAEs were recorded with either treatment. (Web site)

Studies

1. A total of 50% of patients experienced serious adverse events (SAEs) during the studies. (Web site)

Patients Receiving

1. Serious AEs (SAEs) were reported in 2.3, 2.7, and 4.4% of patients receiving 50 mg vildagliptin daily, 100 mg daily, and placebo, respectively. (Web site)

Treatment Arms

1. The incidence of SAEs and fatal AEs was also similar across treatment arms, and increased with increasing disease severity (Table 3).

Treatment Arm

1. AEs and serious AEs (SAEs) were coded using the Medical Dictionary for Regulatory Affairs (MedDRA, version 8.1) and summarized by treatment arm.

Patients

1. The patients with SAEs of inverted T-wave and skeletal cancer discontinued the study. (Web site)

Serious Adverse Events

1. A total of 144 patients on Velcade (44%) reported serious adverse events (SAEs) during the study.

Saes

1. Two serious adverse events (SAEs) were reported on treatment - neither were considered to be related to the study drug. (Web site)
2. Fifty percent of patients reported serious adverse events (SAEs).
3. In the dexamethasone treatment group, the most commonly reported SAEs were pneumonia (7%), pyrexia (4%), and hyperglycemia (3%). (Web site)

Categories

1. Serious Adverse Events
2. Pyrexia
3. Treatment Arm
4. Study Drug
5. Patients Receiving
6. Books about "Saes" in Amazon.com
   

Continue: More Keywords - - - - - - - - - -